Key facts

Financial highlights

7% Revenue growth
10% Operating profit growth
7% Adjusted EPS growth
* Revenue from products and services has been adjusted to exclude income from Nektar between 2006 and 2008. No adjustment has been made to cash generated from operations or PBT before special items for the impact of Nektar.

Operational highlights

>500m devices manufactured every year groupwide
£1m annual cost saving by continuous improvement
9 products in late stage development in Bespak
19.3% Consort Medical’s share in Atlas Genetics
£4.2m invested in R&D

Divisional highlights


  • Strong revenue, margin and profit growth with resilient core markets
  • Production milestones: 500 millionth Diskus and 1 billionth HFA valve manufactured
  • Development of OTS™ Autoinjector
  • Investment in Atlas Genetics for POC diagnostics
£15.6m Operating profit before special items
+8% Revenue growth
+11% Operating profit growth
18.7% Operating margin

King systems

  • Revenue and profit growth in soft markets
  • Launch of King Vision digital video laryngoscope
  • Completion of automation of Flex 2 manufacturing line
  • Steve Davis appointed as Division CEO
£4.8m Operating profit before special items
+3% Revenue growth (CER)
+5% Operating profit growth
11.1% Operating margin

More information


King system
The first lightweight, cost-effective video laryngoscope with a clinician-friendly design, disposable channeled and non-channeled blades and reusable, integrated OLED video display.


King system Specialising in
the design, development
and supply of innovative
devices for delivery of injectable drug products.

Useful downloads